Brief: Theriva Biologics Announces Primary Endpoints For Efficacy And Safety Achieved In VIRAGE Phase 2B Clinical Trial Of VCN-01 With Gemcitabine/NAB-Paclitaxel In Newly-Diagnosed Metastatic Pancreatic Cancer Patients
07/05/2025 12:11
May 7 (Reuters) - Theriva Biologics Inc TOVX.A: THERIVA™ BIOLOGICS ANNOUNCES PRIMARY ENDPOINTS FOR EFFICACY AND SAFETY ACHIEVED IN VIRAGE PHASE 2B CLINICAL TRIAL OF VCN-01 WITH GEMCITABINE/NAB-PACLITAXEL IN NEWLY-DIAGNOSED METASTATIC PANCREATIC CANCER PATIENTS THERIVA BIOLOGICS INC - VCN-01 RECEIVES ORPHAN DRUG AND FAST TRACK DESIGNATION Source text: ID:nGNXsW9GC Further company coverage: TOVX.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025